FBXO8

Across TCGA pan-cancer cohorts, FBXO8 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FBXO8 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher FBXO8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXO8 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CHOL, LUSC, and UCEC are the cancer types where FBXO8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
LUSC	OS	Median	All	0.181	0.776	.006	24	view →
UCEC	DFS	Median	All	0.955	0.618	.017	16	view →
GBM	DFS	Median	All	0.052	0.257	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FBXO8–CHOL (OS)

Open the CHOL breakdown →